ALX Oncology (NASDAQ:ALXO) Rating Reiterated by Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXO)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They currently have a $18.00 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 265.85% from the stock’s current price.

A number of other brokerages have also recently issued reports on ALXO. HC Wainwright decreased their target price on ALX Oncology from $30.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, August 11th. Piper Sandler cut their price objective on ALX Oncology from $48.00 to $8.00 and set an “overweight” rating for the company in a research report on Friday, August 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $21.00.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $4.92 on Thursday. ALX Oncology has a fifty-two week low of $3.94 and a fifty-two week high of $13.97. The business has a 50 day moving average price of $5.63 and a two-hundred day moving average price of $6.06. The company has a quick ratio of 12.49, a current ratio of 12.49 and a debt-to-equity ratio of 0.04. The firm has a market cap of $202.46 million, a PE ratio of -1.54 and a beta of 1.72.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.01. Sell-side analysts expect that ALX Oncology will post -3.16 earnings per share for the current fiscal year.

Insider Transactions at ALX Oncology

In other ALX Oncology news, CAO Shelly Pinto sold 7,345 shares of the company’s stock in a transaction on Thursday, July 6th. The stock was sold at an average price of $6.52, for a total transaction of $47,889.40. Following the transaction, the chief accounting officer now owns 55,713 shares of the company’s stock, valued at approximately $363,248.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold 13,511 shares of company stock valued at $93,148 in the last three months. 50.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Swiss National Bank increased its holdings in ALX Oncology by 8.5% during the 1st quarter. Swiss National Bank now owns 19,200 shares of the company’s stock worth $324,000 after purchasing an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. increased its stake in ALX Oncology by 21.6% in the first quarter. JPMorgan Chase & Co. now owns 19,237 shares of the company’s stock valued at $326,000 after acquiring an additional 3,417 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of ALX Oncology by 58.5% during the first quarter. MetLife Investment Management LLC now owns 10,745 shares of the company’s stock worth $182,000 after buying an additional 3,965 shares in the last quarter. BlackRock Inc. grew its stake in shares of ALX Oncology by 1.1% in the first quarter. BlackRock Inc. now owns 1,355,478 shares of the company’s stock worth $22,907,000 after purchasing an additional 14,907 shares during the last quarter. Finally, Federated Hermes Inc. bought a new stake in ALX Oncology during the first quarter valued at $914,000. Institutional investors and hedge funds own 83.37% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer.